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Objectives: Nuclear magnetic resonance (NMR) spectroscopy has been successfully applied to the measure-
ment of high-density lipoprotein (HDL) particles, providing particle concentrations for total HDL particle number
(HDL-P), HDL subclasses (small, medium, large) and weighted, average HDL size for many years. Key clinical
studies have demonstrated that NMR-measuredHDL-Pwasmore strongly associatedwithmeasures of coronary
artery disease and a better predictor of incident cardiovascular disease (CVD) events thanHDL-cholesterol (HDL-
C). Recently, anNMR-based clinical analyzer, the Vantera®, was developed to allow lipoproteinmeasurements to
be performed in the routine, clinical laboratory setting. The aim of this study was to evaluate and report the per-
formance characteristics for HDL-P quantiﬁed on the Vantera® Clinical Analyzer.
Design and methods: Assay performance was evaluated according to Clinical and Laboratory Standards In-
stitute (CLSI) guidelines. In order to ensure that quantiﬁcation of HDL-P on the Vantera® Clinical Analyzer was
similar to the well-characterized HDL-P assay on the NMR proﬁler, a method comparison was performed.
Results: Thewithin-run andwithin-lab imprecision ranged from2.0% to 3.9%. Linearitywas establishedwith-
in the range of 10.0 to 65.0 μmol/L. The reference intervals were different betweenmen (22.0 to 46.0 μmol/L) and
women (26.7 to 52.9 μmol/L). HDL-P concentrations between two NMR platforms, Vantera® Clinical Analyzer
and NMR Proﬁler, demonstrated excellent correlation (R2 = 0.98).
Conclusions: The performance characteristics, as well as the primary tube sampling procedure for specimen
analysis on the Vantera® Clinical Analyzer, suggest that the HDL-P assay is suitable for routine clinical
applications.© 2014 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Introduction
The inverse association between HDL concentrations and CVD risk is
well established [1]. Results from a number of epidemiologic studies
demonstrated that low HDL-C concentrations were strongly associated
with CVD risk independent of LDL cholesterol (LDL-C) [2–4]. As a result
of these studies, guidelines recognize low HDL-C concentration as a riskDL, high-density lipoprotein;
in; CVD, cardiovascular disease;
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Clinical Chemists. Published by Elsevfactor for CVD [5]. However, recent developments have raised doubts
regarding the relationship between HDL-C and CVD risk as several
clinical trials of agents that substantially raised HDL-C levels failed to
show a reduction in cardiovascular event rates [6,7]. Given what we
now know about the complex nature of HDL, these results are not sur-
prising [8–13]. For example, the protein constituents on HDL particles
vary tremendously depending on the individual'smetabolic and inﬂam-
matory state. Additionally, the phospholipid content of the surface
monolayer and the ratio of cholesteryl esters to triglycerides within
the core of HDL particles differ greatly between individuals, depending
on the inﬂammatory, nutritional and metabolic state of the patient,
leaving HDL-C alone as a poor surrogate biomarker for the number of
circulating HDL particles.
Results from a number of key epidemiological and clinical trials,
including the Multi-Ethnic Study of Atherosclerosis (MESA) [14], the
Heart Protection Study (HPS) [15] and the Justiﬁcation for the Use
of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin
(JUPITER) [16], demonstrated that NMR-measured HDL-P was aier Inc. This is an open access article under the CC BY license
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JUPITER, investigators evaluated the relationship of HDL-C and HDL-P
with CVD risk in more than 10,000 subjects randomized to receive
rosuvastatin or placebo. Similar to results from the HPS, JUPITER
showed a signiﬁcant, strong, inverse association between HDL-P con-
centrations and CVD risk. In contrast, HDL-C was not associated with
CVD risk in statin-treated patients after adjustment for additional lipo-
protein parameters. Therefore, NMR-measured HDL-P provides a more
accurate and reliable measure of HDL quantity than HDL-C.
NMR spectroscopy has been successfully applied to the measure-
ment of HDL particles for many years, providing particle concentrations
for total HDL-P, HDL subclasses (small, medium, large) and weighted,
average HDL size [17]. The lipoprotein proﬁle, delivered via analysis of
a single NMR spectra, also provides average size and particle concentra-
tions for very low density lipoproteins (VLDL), intermediate density
lipoproteins (IDL) and low-density lipoproteins (LDL) [17–19]. Al-
though there is value in evaluating the lipoprotein class and subclass
changes that occur under various disease conditions, each lipoprotein
parameter may in fact have its own unique clinical utility. For example,
measurement of total LDL particle concentration via the NMR LDL-P
assay is employed for the management of LDL related risk and is espe-
cially useful in patients with metabolic disease and type 2 diabetes,
where LDL-C and LDL-P are often discordant [20]. The clinical utility of
HDL-P information is actively being explored based on recent clinical
trials, suggesting that there may be value in knowing a patient's
HDL-P level, especially in cases where there is residual CVD risk
[14–16]. Recently, a clinical NMR instrument, the Vantera NMR
Clinical Analyzer, was developed that addresses the limiting factors
of standard NMR instruments and allows lipoprotein measurements
to be performed in the routine, clinical laboratory setting [20]. The
Vantera Clinical Analyzer received clearance from the Food and
Drug Administration (FDA) as an in vitro diagnostic device in 2012.
The aim of this study was to evaluate and report the performance
that is typically observed for the HDL-P assay as implemented on the
FDA-approved Vantera Clinical NMR Analyzer.
Materials and methods
Specimen collection and preparation
Serum pools and controls were purchased from Solomon Park
Research Laboratories. Controls were prepared by identifying serum
samples with high and low lipoprotein concentrations. Additional
serum pools were prepared in-house from donor subjects recruited at
LipoScience or Mayo Clinic. This study was carried out in accordance
with The Code of Ethics of the World Medical Association (Declaration
of Helsinki), cleared by an Institutional Review Board and all donors
signed consent forms. Specimenswere collectedwith NMR LipoProﬁle®
serum separator tubes (Greiner #456293 or #455232; Greiner Bio-One;
also known as LipoTubes), allowed to clot at room temperature for
30 min, centrifuged at 3,000 rpm for 15 min at room temperature and
promptly stored at 4 °C. For pre-analytical collection tube studies, spec-
imens were drawn into BD Vacutainer serum collection tubes (red-top,
no gel barrier; BD Diagnostics) and allowed to clot as described above,
or in K2-EDTA plasma collection tubes (BD Diagnostics) and processed
per manufacturer instruction.
Acquisition of NMR spectra and data processing
NMR spectra were acquired at the Clinical Laboratory Improvement
Amendments (CLIA) approved laboratory at LipoScience (Raleigh, NC)
using either the Vantera or NMR Proﬁler instruments as previously de-
scribed [20]. Both instruments are equipped with 400 MHz NMR spec-
trometers. In brief, each specimen was diluted with NMR diluent and
delivered into the spectrometer's homogeneousmagnetic ﬁeld througha heated transfer line. Typically, two levels of serum controls were in-
cluded at the beginning and end of each specimen run.
Data acquisition on the NMR Proﬁler was performed as described
previously [19]withwater suppression achieved through presaturation.
Data acquisition on the Vantera was accomplished in a similar fashion
with the exception that water was suppressed using the WET solvent
suppression technique [21]. NMR spectral data were acquired as 5
blocks of 2 scans on the NMR Proﬁler and 3 blocks of 4 scans on the
Vantera for a total acquisition time of 40 and 48 s, respectively. For
both systems, the spectra were acquired with a sweep width of
4496.4 Hz and 9024 data points. The data were processed by zeroﬁlling
to 32 K points and multiplied by a Gaussian function to provide resolu-
tion enhancement prior to Fourier transformation. The methyl signal
envelope appearing between 0.718 and 0.914 ppm was further ana-
lyzed using the LipoProﬁle-3 algorithm, which models the signal as a
combination of lipoprotein and serum protein subcomponent spectra
[17]. The quantiﬁcation of each subcomponent was determined by
linear least-squares singular value decomposition constrained so con-
centrations could not be b0. Total HDL-P concentrationswere calculated
as the sum of the HDL subclasses (large, medium and small) with
particle diameters between 7.3 and 14 nm and reported in units of
μmol/L. The overall measurement time on the Vantera is less than
1 min per sample.
Vantera HDL-P trueness or drift controls
To ensure long-term stability and consistency of Vantera HDL-P
measurements, a set of “trueness or drift controls”was developed. True-
ness controls consisted of three serum controls with assigned HDL-P
values determined across multiple Vantera NMR systems and stored
at−80 °C. These were routinely used to benchmark assay performance
and prevent long-term drift of HDL-P values. Assigned values and un-
certainty (±2*SD) for trueness controls were obtained using three
Vantera NMR instruments, measured twice per day (5 replicates/run)
for 3 days. Imprecision for trueness control value assignment was
typically 3.5–4.0% CV. Trueness control values were used to qualify in-
struments during assignment of values for all subsequent control lots.
Assay performance testing
Sensitivity
Serum pools containing low concentrations of HDL-P (5 pools) were
tested to determine limits of blank (LOB), detection (LOD) and quantita-
tion (LOQ) according to Clinical and Laboratory Standards Institute
(CLSI) guidelines [22] as previously described [20]. Mean concentration
and coefﬁcients of variation (CVs) were calculated for each pool.
Imprecision
Serum pools targeting low, intermediate and high concentrations
were used to determine within-laboratory imprecision and repeatabili-
ty per CLSI guidelines [23]. Testing consisted of duplicate tests run twice
per day for 20 days (n=80) on one Vantera, while within-run impreci-
sion was calculated from 20 replicates.
Linearity
A series of mixtures of high and low serum pools were created to
evaluate assay linearity based on CLSI guidelines [24]. Serum pools
with elevated HDL-P were obtained by pooling serum specimens with
high concentrations of lipoproteins (determined by screening serum
samples using both the Vantera and NMR Proﬁler platforms) and
enriching with addition of HDL isolated by ultracentrifugation. The ex-
pected values came from measuring the concentrations for the serum
pools with the highest and lowest HDL particle concentrations using
the Vantera Clinical Analyzer and calculating the intermediate concen-
trations based on the combinations that were made between these
two pools [25,26]. Specimens with intermediate HDL-P concentrations
Table 1
Within-run imprecision, repeatability, within-laboratory imprecision for HDL-Pmeasured
on the Vantera Clinical Analyzer.
HDL-P (μmol/L)
Low Intermediate High
Within-runb
Mean 27.5 36.9 47.4
SD 0.7 1.3 1.8
CV 2.4% 3.4% 3.9%
Repeatabilitya
Mean 27.1 36.6 45.8
SD 0.5 0.7 0.5
CV 1.9% 2.0% 1.0%
Within-laboratorya
Mean 27.1 36.6 45.8
SD 0.8 0.9 0.9
CV 3.0% 2.4% 2.0%
a Based on CLSI guidelines tested using3 controls, 2 runs per day in duplicate, for 20 days
(total n = 80).
b Based on 1 run of 20 tests.
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tein concentrations in varying proportions. Each mixture was analyzed
four times.
Method comparison
Method comparison studies consistent with CLSI guidelines were
performed to ensure that the performance of the HDL-P assay on the
Vantera Clinical Analyzer was similar to the assay run on the NMRFig. 1. (A) Results of linearity testing for the Vantera HDL-P assay. (B) Comparison of VanteraProﬁler [27]. Samples (n=1522) were tested in singlicate on the refer-
ence (NMR Proﬁler) and comparator (Vantera Clinical Analyzer) NMR
systems over a period of 8 days. The correlation between results gener-
ated on the two NMR platformswas evaluated using Deming regression
analysis.
Reference interval studies
To determine the reference range for the HDL-P assay, samples were
analyzed from healthy adult men and nonpregnant women between
the ages of 18 and 84 years. A description of this normal study popula-
tion has been reported [20]. The HDL-P reference range was estimated
using nonparametric analyses with reference limits at the 2.5th and
97.5th percentiles according to the nonparametric method described
in CLSI guidelines [28]. The reference intervals for men and women
were compared by assessing their median results by a Wilcoxon rank
sum test. HDL-C values were obtained using the standard chemistry
method on a Beckman Coulter analyzer.
In vitro test for interfering substances
A total of 7 endogenous and 23 exogenous substances were tested
for possible assay interference consistent with CLSI guidelines [29] as
previously described [20].
Comparison of collection tubes
Blood from 46 donors was drawn into three different tubes:
LipoTube (serum), BD Vacutainer serum tube (red-top, no gel barrier)
and K2EDTA plasma tube. In order to expand the range of measuredand NMR Proﬁler methods for detection and quantiﬁcation of HDL-P. (C) Residual plot.
Fig. 2. Distribution of HDL-P values for reference range study participants.
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(≤50%) and 2 specimens with elevated analytes were spiked with frac-
tionated HDL (≤10% by volume). Therefore, HDL-P was measured on a
total of 50 specimens. Results for conventional serum and EDTA plasma
tubes were compared to results for the LipoTube by linear regression.
Stability testing
Samples drawn in LipoTubes obtained from three separate studies of
10 donors each (n=30)were used to assess stability of HDL-P. Samples
were stored at 4 °C and aliquots were tested daily for 7 days. Dailymean
results for all donors were evaluated with acceptable differences falling
within ±10% of the day 0 (draw day) mean.
Results
Assay performance
The analytical performance of the NMR-based HDL-P assay, as mea-
sured on the Vantera Clinical Analyzer, was evaluated for the ability to
reliably detect and accurately quantify HDL particles in serum. The aver-
age value obtained when testing replicate blanks (LOB) was 4.2 μmol/L
while the analytical sensitivity or limit of detection (LOD) was
4.6 μmol/L. Testing of nine serum pools, with HDL-P ranging from 4.8
to 7.4 μmol/L, gave a functional sensitivity or limit of quantitation
(LOQ) of 4.8 μmol/L with a CV of b10%. Controls with three varying
concentrations of HDL analytes (low, intermediate and high) were
tested for repeatability, intra-assay (within-run) precision, inter-assay
(within-lab) precision. The CV for the HDL-P assay ranged from 2.4%
to 3.9% for within-run imprecision, from 1.0% to 2.0% for repeatability
and from 2.0% to 3.0% for within-lab imprecision (Table 1).
In order to test the ability of the assay to detect HDL particles, the
measured valueswere plotted against the actual or expected concentra-
tions. Linearity of HDL-P was demonstrated throughout the reportable
range of 10 to 65 μmol/L with a correlation coefﬁcient of R2 = 1.0
(Fig. 1A).
Method comparison
The performance of theHDL-P assay on the Vantera Clinical Analyzer
was found to be similar to the well-characterized HDL-P assay on the
NMR Proﬁler. The linear regression (data not shown) for the HDL-P
data, with the NMR Proﬁler results as the reference method, produced
a slope±95% conﬁdence intervals (CI) of 1.04 (95% CI: 1.03 to 1.05), in-
tercept of−0.58 (95% CI:−0.94 to−0.22) and correlation coefﬁcient
(R2) of 0.98; Deming regression produced a slope of 1.06 (95% CI: 1.05
to 1.08) and an intercept of −1.34 (95% CI: −1.73 to −0.95)
(Fig. 1B). Differences between the HDL-P values and the regression
line (residuals) were plotted against the estimated concentration of
HDL-P. The points on the plot were randomly dispersed around the hor-
izontal axis, suggesting that the results of the two assays were linearly
related with no signiﬁcant bias (Fig. 1C). There also did not appear to
be outliers.
Reference interval determination
A population of healthy individuals (n = 452) was used to deter-
mine the reference interval for the HDL-P assay. Fig. 2 shows the distri-
bution of HDL-P values in this population. The mean HDL-P value was
37.0 ± 6.7 μmol/L, themedianwas 36.6 μmol/L and the reference inter-
val was 24.4–51.4 μmol/L. The reference interval for the HDL-P assay
showed signiﬁcant differences between genders (men = 22.0–46.0
and women = 26.7–52.9 μmol/L) as did the medians (men = 34.4
and women 37.8 μmol/L) and the means (men = 34.6 ± 6.2 and
women 38.2 ± 6.6 μmol/L) (p = 0.001). The HDL-C results from the
same reference population were compared to the HDL-P results(Fig. 2). The mean HDL-C was 57 ± 14 mg/dL. HDL-C concentrations
below 40mg/dL are classiﬁed by National Cholesterol Education Panel's
Adult Treatment Panel (ATP) III guidelines [30] as low, signifying that a
patientmay be at higher risk for CVD. In addition, anHDL-C value of b40
mg/dL has been recommended as a factor used to assess an individual's
risk for atherosclerotic cardiovascular disease and need for lipid-
lowering therapy (AHA/ACC guidelines). In this population, 40 mg/dL
corresponded to the 10th percentile of the HDL-C values and an
HDL-P concentration of 28.7 μmol/L (Fig. 2).In vitro test for interfering substances
Thirty substances were tested in vitro for interference with HDL-P
quantitation. As per CLSI standards for in vitro interference testing,
drug concentrations tested are representative of parent concentrations
and do not reﬂect therapeutic concentrations of the active or inactive
metabolites of these agents. Results (Table 2) demonstrated no interfer-
ence or differences that were N10% at the highest level tested for 27 of
the 30 substances tested. Three substances (acetylsalicylic acid, nicotin-
ic acid and clopidogrel hydrogen sulfate) showed potential interference
with theHDL-P assay in the initial screening andwere tested atmultiple
concentrations to identify levels at which interference was signiﬁcant
(Table 2). Acetylsalicylic acid at concentrations N1.7 mM (N1536 mg)
(therapeutic range= 0.7–2.2 mM or 630–1980 mg) resulted in HDL-P
values that were 10–20% lower, while nicotinic acid at concentrations
N2.6 mM (N1850 mg) resulted in HDL-P values that were 10–15%
lower (therapeutic range ≤2.8 mM or ≤2050 mg). Upon retesting,
however, neither substance produced an effect N10% on the HDL-P
Table 2
Summary of interference testing for the NMR HDL-P assay measured on the Vantera Clinical Analyzer.
Substance Drug name Test concentration Concentration eliciting interference
Bilirubin, unconjugated – 200 μg/mL (342 μM)
Bilirubin, conjugated – 289 μg/mL (342 μM)
Creatinine – 50 μg/mL (442 μM)
Hemoglobin – 2 mg/mL
Protein/albumina – 0–60 mg/mL (6.0 g/dL)
Urea – 2.6 mg/mL (43 mM)
Uric acid – 235 μg/mL (1.4 mM)
Acetaminophen Tylenol 200 μg/mL (1.32 mM)
Acetylsalicylic acid Aspirin 0–660 μg/mL (3.62 mM) N1.7 mM (1536 mg)b
Atorvastatin Lipitor 600 μg Eq/mL
Clopidogrel hydrogensulfate Plavix 0–360 μg/mL N107 μg/mL (535 mg)
Enalaprilat dihydrate Vasotec 0.33 μg/mL (0.86 μM)
Fenoﬁbrate Tricor 0–45 μg/mL (125 μM)
Furosemide Lasix 60 μg/mL (181 μM)
Glipizide Glucotrol 2.0 μg/mL (4.48 μM)
Heparin Lovenox 3000 U/L
Hydralazine hydrochloride Apresoline 180 μg/mL
Ibuprofen sodium salt Advil 0–560 μg/mL (2425 μM)
Isosorbide dinitrate Isordil 150 ng/mL (636 nM)
Menhaden oil Fish oil 2.4 mg/mL
Metformin hydrochloride Glucophage 600 μg/mL
Metoprolol tartrate Lopressor 13 μg/mL (18.7 μM)
Naproxen sodium Aleve 550 μg/mL (2170 μM)
Nicotinic acid sodium salt Vitamin B3, Niacin 0–1.2 mg/mL N2.6 mM (1850 mg)b
Nifedipine Adalat 0.4 μg/mL (1.16 μM)
Pioglitazone hydrochloride Actos 27 μg/mL
Piroxicam Feldene 60 μg/mL (181 μM)
Pravastatin Pravachol 48 μg/mL
Salicylic acid – 0–599 μg/mL (4.34 mM)
Simvastatin Zocor 48 μg/mL
Test concentrations were obtained from CLSI EP7-A2 guidelines Appendix C, where available.
a Concentration range reﬂects added albumin not including endogenous albumin.
b Borderline effect that does not reproducibly exceed interference criteria of 10% difference from control.
152 S.P. Matyus et al. / Clinical Biochemistry 48 (2015) 148–155values even at the highest concentrations. Clopidogrel hydrogen sulfate
at concentrationsN107 μg/mL (535mg) resulted in a 10–15% increase in
HDL-P (therapeutic range ≤120 μg/mL or ≤600 mg).Comparison of specimen collection tubes
Several types of specimen collection tubes were compared to
LipoTubes for their suitability in the HDL-P assay. The results performedFig. 3. Comparison of collection tubes. (A) Results for BD Vacutainer serum tubes (no gel barrie
tubes compared to NMR LipoProﬁle test serum tube.on specimens collected in LipoTubes were plotted against results ob-
tained in conventional red-top serum tubes (no gel barrier) (Fig. 3A).
A linear regression analysis was performed, and the resulting line gave
a slope of 0.99 (R2 = 0.99). Moreover, red-top serum tubes showed
no signiﬁcant bias based on either 95% conﬁdence intervals around
the correlation slope and intercept, or estimation of bias from Bland–
Altman residual plots (data not shown). For the HDL-P assay performed
on specimens collected in EDTA plasma tubes (Fig. 3B), the resulting lin-
ear regression produced a slope of 0.97 (R2 = 0.99). The HDL-P assayr) compared to NMR LipoProﬁle test serum tube (gel barrier). (B) Results for EDTA plasma
Table 3
Stability data for HDL-P assay measured on the Vantera Clinical Analyzer.
Day N Mean HDL-P (μmol/L) % Bias
0 30 36.1 n/a
1 30 35.3 −2.2
2a 20 35.1 −1.9
3a 20 34.7 −3.0
4 30 34.8 −3.7
5 30 34.2 −5.4
6 30 34.2 −5.3
7b 29 33.9 −5.2
a Days 2 and 3 not observed in 1 of 3 studies (n = 20). % Bias calculated relative tomean
day 0 HDL-P of 35.8 μmol/L.
b Day 7missing 1 subject due to short draw (n = 29). % Bias calculated relative tomean
day 0 HDL-P of 35.8 μmol/L.
153S.P. Matyus et al. / Clinical Biochemistry 48 (2015) 148–155results in EDTA plasma tubes, however, were modestly (3–7%) lower
than results from the same specimens collected in LipoTubes.
Stability testing
The stability of HDL-P as measured on the Vantera Clinical Analyzer
was evaluated in thirty serum samples stored for up to 7 days at 4 °C.
Measurements were deemed acceptable if they were within 10% of
the day 0 mean HDL-P. Results demonstrated that HDL-P was stable
out to day 7 at 4 °C with changes ≤5.4% (Table 3).
Discussion
Several epidemiological studies have served the role of establishing
the inverse association between HDL-C and the risk of experiencing a
CVDevent [2–4]. The association of HDL-Cwith CVDhas been attributed
to several anti-atherogenic roles that HDL particles play, including the
promotion of cholesterol efﬂux from macrophages in the arterial wall
[31]. However, recent developments have raised doubts regarding the
relationship between HDL-C and CVD risk. Clinical trials of agents that
substantially raised HDL-C levels failed to show a reduction in CVD
event rates [6,7]. The failures of these early agents highlighted the fact
that investigators had not fully comprehended the complex nature of
HDL particles at the time the targets for HDL-C raising therapies were
chosen [8–12]. Recent scientiﬁc evidence has shown that HDL particles
are highly diverse in molecular composition (e.g., proteome, lipidome)
and function, both of which vary depending on the inﬂammatory, nutri-
tional, metabolic or disease state of the patient. This new appreciation
for HDL particle diversity has led many to believe that HDL-C is a poor
surrogate for the number of circulating HDL and that raising HDL parti-
cle numbers and enhancing their function are the more relevant end
points to target with an intervention aimed at reducing risk of CVDTable 4
Comparison of NMR and CIM HDL-P assays.
HDL-P assay Assay characteristics Strengths
NMR • Intra-assay CV 3.2%
• Inter-assay CV 2.5%
• Direct measurement withou
or sample manipulation
• Fully automated platform
• High throughput
CIM • Intra-assay CV 6.2%
• Inter-assay CV 11.4%
• Measures particle size using
• Increased accuracy over orig
due to calibrationevents, especially in patients whose LDL levels have already been
lowered by statin treatment [6,7,11,12,32]. In support, several recent
epidemiological and clinical trials showed that NMR-measured HDL-P
is a better measure of CVD risk than HDL-C [14–16]. Consideration of
these facts have led the developers of newer HDL modulating agents
to measure HDL-P and HDL function rather than relying solely on
HDL-C. Here we report the analytical performance characteristics for
theHDL-P assay on the Vantera Clinical Analyzer. Based on this analysis,
NMR HDL-P exhibited acceptable sensitivity, precision and stability,
making it a reliable assay for quantiﬁcation of HDL particle number in
the routine clinical laboratory.
Besides HDL-C and NMR-derived HDL-P, two additional measures
have been used to estimate circulating concentrations of HDL particles:
(1) apoA-I by ELISA or nephelometry and (2) HDL-P by ion mobility
spectrometry. Unlike LDL particles that contain one apolipoprotein B
(apoB)molecule per particle, allowing apoB to be a fairly good surrogate
marker for circulating LDL-P, HDL particles contain varying numbers of
apoA-I molecules per particle. The number of apoA-I particles depends
on the size of the particle aswell as the number of auxiliary proteins car-
ried per particle under various inﬂammatory or metabolic conditions
[8–13]. Therefore, apoA-I is not a good surrogate marker for HDL-P.
Ionmobility (IM) spectrometry, where ionized lipoproteins are separat-
ed by size and charge, measures HDL particles that have been isolated
by ultracentrifugation [33]. Recently, a new calibrated method for mea-
suring HDL-P via ion mobility (CIM) was reported [34]. CIM appears to
be an advancement over IM as the estimated stoichiometry of apoA-I
molecules per HDL particle was reported to be on average 3–4, which
is in closer agreement with current structural models than the average
estimated by the original method (13 apoA-I per particle) [35,36].
NMR, on the other hand, estimates b2.0 copies of apoA-I per particle,
which is closer to the original IM method, but slightly lower than
what the structural models suggest may be the true average. As the ed-
itorial that accompanied the journal article describing CIM illustrated,
there are strengths and limitations to both NMR and CIM with respect
to estimating circulating concentrations of HDL particles (Table 4) [37].
One of the limitations for either NMR or CIM measurement of HDL-P is
that to date there has been no reference method with standard calibra-
tion of HDL particles in a complex solution such as serum to which an
HDL-P assay could be compared for accuracy. Practically speaking, how-
ever, NMR is currently the only HDL-P assay with results that have re-
peatedly been shown to be associated with CVD outcomes and are
available in the clinical laboratory setting.
Besides measurements of lipoprotein particle numbers and size,
NMR is capable of simultaneously proﬁling a range of biological mole-
cules and metabolites from a single sample, making it an attractive
tool for applications related to personalized diagnostics. The ability to
proﬁle complex clinical specimens requires that interference from
drugs and other substances be kept at a minimum. NMR technology is
not inﬂuenced by the type of interferences common to chemical
methods. Since all theNMR-based lipoprotein information are extractedLimitations
t HDL isolation • Measures particle size using the lipid component only
all components
inal IM method
• HDL must be isolated by ultracentrifugation which can
lead to loss of apolipoproteins therefore redistribution
of sizes may occur
• Extrapolation of CIM values back to circulating HDL-P
concentrations requires careful accounting of volumes,
dilutions and sample loss
• Labor intensive; low throughput
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methyl signal that appears in the lipid region of 0.7–0.9 ppm can poten-
tially interfere with the lipoprotein analysis. Dramatic changes in the
matrix including ionic strength and pH can have an effect on the chem-
ical shift of the lipid signal, though this is unlikely to occurwith samples
obtained under normal specimen handling conditions. However, the
in vitro method recommended by CLSI for evaluating substances for
assay interference, which entails spiking substances into plasma or
serum, may introduce artiﬁcial changes to the spectra that are unlikely
to occur with circulating concentrations of drug after oral administra-
tion. In the current study, in vitro addition of substances to serum re-
vealed that nicotinic acid, acetylsalicylic acid and clopidogrel affected
theHDL-P results. The effects seenwith nicotinic acid and acetylsalicylic
acid were borderline and did not repeat upon further testing; therefore
they are not of concern. Furthermore, the concentrations of these drugs
that interferedwith the HDL-P values in vitro are not expected to be ob-
served in blood samples obtained from patients taking therapeutic
doses. For example, nicotinic acid is normally taken in the evening and
is rapidly metabolized after oral administration (half-life = 20–45
min). Therefore, circulating concentrations of nicotinic acid are not like-
ly to be high when a patients serum samples is drawn for a lipoprotein
analysis, in the morning after overnight fasting. Similarly, the recom-
mended doses of acetylsalicylic acid or aspirin are 81–160 mg for pre-
vention of CVD and 325–650 mg for various other indications. The
results of this study revealed that a patient would have to achieve a cir-
culating concentration of acetylsalicylic acid N1.73 mM in order to elicit
an effect on the HDL-P results. This is not likely to occur because aspirin
is also rapidly metabolized (half-life = 15 min) and the major metabo-
lite of aspirin, salicylic acid, did not affect HDL-P values (Table 2).
Clopidogrel is an inactive pro-drug that is rapidly converted to the ac-
tive form (30–60 min) after oral administration [38]. The clopidogrel
metabolites do not contain methyl groups that would arise within the
lipid region of the NMR spectrum nor are they hydrophobic enough to
bind to the lipoprotein particles and affect their structures. Therefore,
they are unlikely to interfere with lipoprotein particle quantitation
in vivo. Unfortunately, the clopidogrel metabolites were not available
for testing at the time this studywas conducted. In conclusion, although
in vitro testing in this study indicated some sources of potential interfer-
ence, this does not prohibit reliable HDL-P quantitation since most
changes were observed at concentrations above the therapeutic win-
dow or were not likely to affect NMR spectra obtained from patients
taking therapeutic doses of these substances.
The successful development of a method to measure HDL-P on a
fully automated NMR platform allows decentralized testing in the clin-
ical laboratory setting and creates the opportunity for NMR-based test-
ing across a broader range of clinical applications. The Vantera Clinical
Analyzer has been successfully integrated into routine clinical laborato-
ry operations within several national reference laboratories and large
healthcare systems within the United States. Current and future efforts
are focused on expanding the menu of NMR-based tests that are
available for physicians to make informed decisions on patient care, es-
pecially in an erawhen personalizedmedicine, using tests that are inex-
pensive and widely available, is becoming highly desirable.
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